Y-mAbs Therapeutics (NASDAQ:YMAB) Announces Earnings Results

Y-mAbs Therapeutics (NASDAQ:YMAB) announced its quarterly earnings data on Friday. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02), RTT News reports. Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. The firm had revenue of $18.46 million during the quarter, compared to analyst estimates of $23.38 million. During the same quarter in the previous year, the business earned ($0.18) EPS. Y-mAbs Therapeutics updated its FY 2024 guidance to EPS.

Y-mAbs Therapeutics Stock Performance

NASDAQ YMAB traded down $0.07 during trading hours on Friday, hitting $15.48. 580,428 shares of the company’s stock were exchanged, compared to its average volume of 330,577. The business’s 50 day moving average is $14.11 and its 200-day moving average is $13.17. Y-mAbs Therapeutics has a 12-month low of $4.69 and a 12-month high of $20.90. The firm has a market capitalization of $689.94 million, a P/E ratio of -27.64 and a beta of 0.68.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on YMAB. Wedbush reissued an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, September 9th. Canaccord Genuity Group reissued a “buy” rating and set a $26.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Morgan Stanley reduced their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a research report on Tuesday, August 13th. Finally, BMO Capital Markets dropped their price objective on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Y-mAbs Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $21.14.

Insider Buying and Selling at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 65,000 shares of the stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $13.47, for a total transaction of $875,550.00. Following the transaction, the insider now directly owns 97,681 shares in the company, valued at $1,315,763.07. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, insider Thomas Gad sold 65,000 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $13.47, for a total transaction of $875,550.00. Following the completion of the sale, the insider now directly owns 97,681 shares in the company, valued at $1,315,763.07. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Joris Wilms sold 5,000 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the transaction, the chief operating officer now directly owns 30,600 shares in the company, valued at $449,514. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 100,000 shares of company stock worth $1,338,100 in the last 90 days. 22.50% of the stock is owned by company insiders.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.